Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Sanofi's Sarclisa shows subcutaneous form is as effective as IV in treating multiple myeloma.

flag Sanofi's Sarclisa, used to treat relapsed multiple myeloma, has shown its subcutaneous form is as effective as the intravenous version in a phase 3 study. flag The trial, using the enFuse hands-free delivery system, met its primary goals, suggesting the subcutaneous form offers similar outcomes and potentially better convenience for patients. flag Full results will be shared at a future medical conference, and Sanofi plans to submit the subcutaneous form for approval in the US and EU in the first half of 2025.

7 Articles

Further Reading